These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
89 related articles for article (PubMed ID: 862950)
41. Stability-indicating HPTLC determination of imatinib mesylate in bulk drug and pharmaceutical dosage form. Vadera N; Subramanian G; Musmade P J Pharm Biomed Anal; 2007 Jan; 43(2):722-6. PubMed ID: 16920319 [TBL] [Abstract][Full Text] [Related]
42. Analytical uses of charge-transfer complexes: determination of pure and dosage forms of piperazine. Muralikrishna U; Krishnamurthy M; Rao NS Analyst; 1984 Oct; 109(10):1277-9. PubMed ID: 6524673 [No Abstract] [Full Text] [Related]
43. Stability-indicating UPLC method for determination of Imatinib Mesylate and their degradation products in active pharmaceutical ingredient and pharmaceutical dosage forms. Nageswari A; Reddy KV; Mukkanti K J Pharm Biomed Anal; 2012 Jul; 66():109-15. PubMed ID: 22502910 [TBL] [Abstract][Full Text] [Related]
44. Electrochemistry of potential bioreductive alkylating quinones: its use in the development of new aziridinylquinones. Driebergen RJ; Holthuis JJ; Hulshoff A; Postma-Kelder SJ; Verboom W; Reinhoudt DN; Lelieveld P Anticancer Res; 1986; 6(4):605-19. PubMed ID: 3752941 [TBL] [Abstract][Full Text] [Related]
45. [On the medical properties of dipin in neoplasms of the hematopoietic system]. KOMISSAROV AN; KOMISSAROVA NE Vopr Onkol; 1960; 6():79-86. PubMed ID: 14410811 [No Abstract] [Full Text] [Related]
46. Spectrophotometric determination of piperazine and its salts in pharmaceuticals. Abou-Ouf AM; Walash MI; Rizk MS; Ibrahim FA J Assoc Off Anal Chem; 1979 Sep; 62(5):1138-40. PubMed ID: 528460 [TBL] [Abstract][Full Text] [Related]
47. [Induction of dominant lethals in mice by fotrin]. Revazova IuA; Radchenko LU Genetika; 1976; 12(2):165-7. PubMed ID: 1269926 [No Abstract] [Full Text] [Related]
48. [Study on an unknown complex by gas chromatography/infrared spectrometry]. Chen RP; Yu JQ; Zheng Y; Ren Q Guang Pu Xue Yu Guang Pu Fen Xi; 2005 Feb; 25(2):219-21. PubMed ID: 15852860 [TBL] [Abstract][Full Text] [Related]
49. [Biochemical and pharmacological properties of new 2-substituted aziridines. Contribution to experimental tumor research]. Bicker U Fortschr Med; 1978 Mar; 96(12):661-4. PubMed ID: 631706 [TBL] [Abstract][Full Text] [Related]
50. [The cytogenetic effect of the new antitumor preparation fotrin in a human lymphocyte culture]. Azhaev SA Biull Eksp Biol Med; 1974 Sep; 78(9):106-8. PubMed ID: 4462655 [No Abstract] [Full Text] [Related]
51. Phase II trial of diaziquone in advanced renal adenocarcinoma. Hansen M; Gallmeier WM; Vermorken J; Holdener E; Hansen HH; Renard J; Rozencweig M Cancer Treat Rep; 1984; 68(7-8):1055-6. PubMed ID: 6744342 [No Abstract] [Full Text] [Related]
52. [Experimental study of the toxicity and antitumor activity of halide derivatives of ethyleneimine]. Demirchoglian IG; Papoian SA; Babasian OV; Galstian DA; Oganesian MS Zh Eksp Klin Med; 1976; 16(5):33-8. PubMed ID: 1023706 [No Abstract] [Full Text] [Related]
53. Determination of azelaic acid in pharmaceuticals and cosmetics by RP-HPLC after pre-column derivatization. Ferioli V; Rustichelli C; Vezzalini F; Gamberini G Farmaco; 1994 Jun; 49(6):421-5. PubMed ID: 8074784 [TBL] [Abstract][Full Text] [Related]
54. Toxicity of aziridinylbenzoquinone administered Iv to beagle dogs. Hacker MP; Hong CB; McKee MJ; Unwin SE; Urbanek MA Cancer Treat Rep; 1982 Oct; 66(10):1845-51. PubMed ID: 7127322 [No Abstract] [Full Text] [Related]
55. Phase II clinical trial of diaziquone in bronchogenic carcinoma. Chiuten DF; Umsawasdi T; Dhingra HM; Murphy WK; Spitzer G; Carr DT; Bodey GP; Valdivieso M Cancer Treat Rep; 1985; 69(7-8):921-2. PubMed ID: 4016800 [No Abstract] [Full Text] [Related]
56. Phase II study of diaziquone in patients with advanced carcinoma of the lung. Frytak S; Eagan RT; Creagan ET; Nichols WC Cancer Treat Rep; 1984 Sep; 68(9):1193-4. PubMed ID: 6478455 [No Abstract] [Full Text] [Related]
57. Phase II trial of aziridinylbenzoquinone (AZQ) in patients with refractory lymphoma. McLaughlin P; Cabanillas F; Bedikian AY; Bodey GP Cancer Treat Rep; 1983 May; 67(5):507-8. PubMed ID: 6850666 [No Abstract] [Full Text] [Related]
58. Identification of imatinib mesylate degradation products obtained under stress conditions. Szczepek WJ; Kosmacińska B; Bielejewska A; Łuniewski W; Skarzyński M; Rozmarynowska D J Pharm Biomed Anal; 2007 Apr; 43(5):1682-91. PubMed ID: 17307328 [TBL] [Abstract][Full Text] [Related]
59. [Cytogenetic effect of ethylenimine derivatives in cultures of human lymphocytes. I. Experimental findings and mathematical verification of quantitative patterns]. Iakovenko KN; Azhaev SA; Bochkov NP Genetika; 1974; 10(10):135-43. PubMed ID: 4220049 [No Abstract] [Full Text] [Related]
60. [Dynamics of the development of oval cell population induced in the liver by dipin and partial hepatectomy]. Radaeva (Pronina) SA; Faktor VM Biull Eksp Biol Med; 1990 May; 109(5):514-7. PubMed ID: 2378977 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]